Monocarboxylate transporter 1 contributes to growth factorinduced tumor cell migration independent of transporter activity

Oncotarget

Volumn 7, Issue 22, 2016, Pages 32695-32706

  Gray, Alana L ^a   Coleman, David T ^a   Shi, Runhua ^a   Cardelli, James A ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Cancer; EGF; HGF; MCT1; Motility

Indexed keywords

ADENOSINE TRIPHOSPHATE; EPIDERMAL GROWTH FACTOR RECEPTOR; LACTIC ACID; MONOCARBOXYLATE TRANSPORTER 1; MONOCARBOXYLATE TRANSPORTER 4; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; COTRANSPORTER; EPIDERMAL GROWTH FACTOR; MET PROTEIN, HUMAN; MONOCARBOXYLATE TRANSPORT PROTEIN 1; MONOCARBOXYLATE TRANSPORTER; MUSCLE PROTEIN; SLC16A4 PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MEMBRANE PERMEABILITY; ONCOLOGICAL PARAMETERS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; WESTERN BLOTTING; CELL MOTION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; PHOSPHORYLATION; TIME FACTOR; TUMOR CELL LINE; TUMOR INVASION;

CELL LINE, TUMOR; CELL MOVEMENT; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE GROWTH FACTOR; HUMANS; LACTIC ACID; MONOCARBOXYLIC ACID TRANSPORTERS; MUSCLE PROTEINS; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MET; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SYMPORTERS; TIME FACTORS; TRANSFECTION;

EID: 84973577774     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9016     Document Type: Article

References (47)

1. Heron M. Deaths: Leading causes for 2011. Natl Vital Stat Rep. 2015; 64:1-96.
2. Abella JV, Parachoniak CA, Sangwan V, Park M. Dorsal Ruffle Microdomains Potentiate Met Receptor Tyrosine Kinase Signaling and Down-regulation. J Biol Chem. 2010; 285:24956-24967.
3. Valastyan S, Weinberg RA. Tumor Metastasis: Molecular Insights and Evolving Paradigms. Cell. 2011; 147:275-292.
4. Waclaw B, Bozic I, Pittman ME, Hruban RH, Vogelstein B, Nowak MA. A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity. Nature. 2015; 525:261-264.
5. Kolch W, Halasz M, Granovskaya M, Kholodenko BN. The dynamic control of signal transduction networks in cancer cells. Nat Rev Cancer. 2015; 15:515-527.
6. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014; 15:178-196.
7. Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer. 2010; 10:130-137.
8. Roskoski Jr R. A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacol Res. 2015; 100:1-23.
9. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012; 12:89-103.
10. Sadiq AA, Salgia R. MET As a Possible Target for Non- Small-Cell Lung Cancer. J Clin Oncol. 2013; 31:1089-1096.
11. Arteaga CL, Engelman JA. ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics. Cancer Cell. 2014; 25:282-303.
12. Chang K, Karnad A, Zhao S and Freeman JW. Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets. Oncotarget. 2015; 6:3507-3518. doi: 10.18632/oncotarget.3420.
13. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 2012; 487:505-509.
14. Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W, Lathan C, Marcoux JP, Du J, Okuda K, Capelletti M, Shimamura T, Ercan D, et al. A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors. Cancer Res. 2011; 71:6051-6060.
15. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale C-M, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. Science. 2007; 316:1039-1043.
16. Wilson FH, Johannessen CM, Piccioni F, Tamayo P, Kim JW, Van Allen EM, Corsello SM, Capelletti M, Calles A, Butaney M, Sharifnia T, Gabriel SB, Mesirov JP, et al. A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer. Cancer Cell. 2015; 27:397-408.
17. Petti C, Picco G, Martelli ML, Trisolini E, Bucci E, Perera T, Isella C, Medico E. Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells. Oncotarget. 2014; 6:221-233. doi: 10.18632/oncotarget.2771.
18. Halestrap A, Meredith D. The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflug Arch Eur J Phy. 2004; 447:619-628.
19. Dimmer K-S, Friedrich B, Lang F, Deitmer JW, BröEr S. The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem J. 2000; 350:219-227.
20. Wilson MC, Jackson VN, Heddle C, Price NT, Pilegaard H, Juel C, Bonen A, Montgomery I, Hutter OF, Halestrap AP. Lactic acid efflux from white skeletal muscle is catalyzed by the monocarboxylate transporter isoform MCT3. J Biol Chem. 1998; 273:15920-15926.
21. Spugnini EP, Sonveaux P, Stock C, Perez-Sayans M, De Milito A, Avnet S, Garcìa AG, Harguindey S, Fais S. Proton channels and exchangers in cancer. BBA-Biomembranes. 2015; 1848:2715-2726.
22. Gupta N, Martin PM, Prasad PD, Ganapathy V. SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter. Life Sci. 2006; 78:2419-2425.
23. Hussien R, Brooks GA. Mitochondrial and plasma membrane lactate transporter and lactate dehydrogenase isoform expression in breast cancer cell lines. Physiol Genomics. 2011; 43:255-264.
24. Fang J, Quinones QJ, Holman TL, Morowitz MJ, Wang Q, Zhao H, Sivo F, Maris JM, Wahl ML. The H+-Linked Monocarboxylate Transporter (MCT1/SLC16A1): A Potential Therapeutic Target for High-Risk Neuroblastoma. Mol Pharmacol. 2006; 70:2108-2115.
25. Choi J-W, Kim Y, Lee J-H, Kim Y-S. Prognostic Significance of Lactate/Proton Symporters MCT1, MCT4, and Their Chaperone CD147 Expressions in Urothelial Carcinoma of the Bladder. Urology. 2014; 84:245.e249-245.e215.
26. Kim Y, Choi JW, Lee JH, Kim YS. Expression of lactate/H(+) symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: immunohistochemical and The Cancer Genome Atlas data analyses. Hum Pathol. 2015; 46:104-112.
27. Pinheiro C, Granja S, Longatto-Filho A, Faria AM, Fragoso MC, Lovisolo SM, Lerario AM, Almeida MQ, Baltazar F, Zerbini MC. Metabolic reprogramming: a new relevant pathway in adult adrenocortical tumors. Oncotarget. 2015; 6:44403-44421. doi: 10.18632/oncotarget.5623.
28. Vegran F, Boidot R, Michiels C, Sonveaux P, Feron O. Lactate Influx through the Endothelial Cell Monocarboxylate Transporter MCT1 Supports an NF-kB/IL-8 Pathway that Drives Tumor Angiogenesis. Cancer Res. 2011; 71: 2550-2560.
29. Sonveaux P, Copetti T, De Saedeleer CJ, Vegran Fdr, Verrax J, Kennedy KM, Moon EJ, Dhup S, Danhier P, Frãcrart Fo, Gallez B, Ribeiro A, Michiels C, et al. Targeting the lactate transporter MCT1 in endothelial cells inhibits lactateinduced HIF-1 activation and tumor angiogenesis. PLoS One. 2012; 7:e33418.
30. Hsu Y-H, Yao J, Chan L-C, Wu T-J, Hsu JL, Fang Y-F, Wei Y, Wu Y, Huang W-C, Liu C-L, Chang Y-C, Wang M-Y, Li C-W, et al. Definition of PKC-a, CDK6, and MET as Therapeutic Targets in Triple-Negative Breast Cancer. Cancer Res. 2014; 74:4822-4835.
31. Knight JF, Lesurf R, Zhao H, Pinnaduwage D, Davis RR, Saleh SM, Zuo D, Naujokas MA, Chughtai N, Herschkowitz JI, Prat A, Mulligan AM, Muller WJ, et al. Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer. P Natl Acad Sci U S A. 2013; 110:E1301-1310.
32. Raghav KP, Wang W, Liu S, Chavez-MacGregor M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein GR Jr, Gonzalez-Angulo AM. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res. 2012; 18:2269-2277.
33. Ryan CJ, Rosenthal M, Ng S, Alumkal J, Picus J, Gravis G, Fizazi K, Forget F, Machiels JP, Srinivas S, Zhu M, Tang R, Oliner KS, et al. Targeted MET inhibition in castrationresistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res. 2013; 19:215-224.
34. Lucas JM, Heinlein C, Kim T, Hernandez SA, Malik MS, True LD, Morrissey C, Corey E, Montgomery B, Mostaghel E, Clegg N, Coleman I, Brown CM, et al. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov. 2014; 4:1310-1325.
35. Kirk P, Wilson MC, Heddle C, Brown MH, Barclay AN, Halestrap AP. CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. EMBO J. 2000; 19:3896-3904.
36. Manning Fox JE, Meredith D, Halestrap AP. Characterisation of human monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal muscle. J Physiol. 2000; 529:285-293.
37. Morris M, Felmlee M. Overview of the Proton-coupled MCT (SLC16A) Family of Transporters: Characterization, Function and Role in the Transport of the Drug of Abuse ß-Hydroxybutyric Acid. The AAPS Journal. 2008; 10: 311-321.
38. Polanski R, Hodgkinson CL, Fusi A, Nonaka D, Priest L, Kelly P, Trapani F, Bishop PW, White A, Critchlow SE, Smith PD, Blackhall F, Dive C,et al. Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer. Clin Cancer Res. 2014; 20:926-937.
39. Le Floch R, Chiche J, Marchiq I, Naiken T, Ilk K, Murray CM, Critchlow SE, Roux Dl, Simon M-P, Pouyssãcgur J. CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. P Natl Acad Sci USA. 2011; 108:16663-16668.
40. Critchlow SE, Hopcroft L, Mooney L, Curtis N, Whalley N, Zhong H, Logie A, Revill M, Xie L, Zhang J, Yu D-H, Murray C, Smith PD. Abstract 3224: Pre-clinical targeting of the metabolic phenotype of lymphoma by AZD3965, a selective inhibitor of monocarboxylate transporter 1 (MCT1). Cancer Res. 2012; 72:3224.
41. Doherty JR, Yang C, Scott KEN, Cameron MD, Fallahi M, Li W, Hall MA, Amelio AL, Mishra JK, Li F, Tortosa M, Genau HM, Rounbehler RJ, et al. Blocking Lactate Export by Inhibiting the Myc Target MCT1 Disables Glycolysis and Glutathione Synthesis. Cancer Res. 2014; 74:908-920.
42. Lacoste C, Herve J, Bou Nader M, Dos Santos A, Moniaux N, Valogne Y, Montjean R, Dorseuil O, Samuel D, Cassio D, Portulano C, Carrasco N, Brechot C, et al. Iodide transporter NIS regulates cancer cell motility and invasiveness by interacting with the Rho guanine nucleotide exchange factor LARG. Cancer Res. 2012; 72:5505-5515.
43. Furge KA, Kiewlich D, Le P, Vo MN, Faure M, Howlett AR, Lipson KE, Vande Woude GF, Webb CP. Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase. P Natl Acad Sci U S A. 2001; 98:10722-10727.
44. Basilico C, Hultberg A, Blanchetot C, de Jonge N, Festjens E, Hanssens V, Osepa SI, De Boeck G, Mira A, Cazzanti M, Morello V, Dreier T, Saunders M, et al. Four individually druggable MET hotspots mediate HGF-driven tumor progression. J Clin Invest. 2014; 124:3172-3186.
45. Webb CP, Taylor GA, Jeffers M, Fiscella M, Oskarsson M, Resau JH, Vande Woude GF. Evidence for a role of Met- HGF/SF during Ras-mediated tumorigenesis/metastasis. Oncogene. 1998; 17:2019-2025.
46. Bos JL. ras Oncogenes in Human Cancer: A Review. Cancer Res. 1989; 49:4682-4689.
47. Kalluri R, Weinberg RA. The basics of epithelialmesenchymal transition. J Clin Invest. 2009; 119:1420-1428.